Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
NEW YORK, March 28, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Regulus Therapeutics Inc. (“Regulus”) (NASDAQ:RGLS) between February 17, 2016 and January 27, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Jin v. Regulus Therapeutics Inc., et al. (Case No. 17cv0267 LAB JMA) in the USDC for the Southern District of California. To get more information go to:
http://www.zlk.com/pslra/regulus-therapeutics?wire-3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the Class Period, Regulus made materially false and/or misleading statements and/or failed to disclose that: (i) RG-101 was not safe and well tolerated by all patients in the ongoing studies, (ii) cases of serious adverse events (“SAE”) were discovered, (iii) the SAEs were proof of serious concerns about the safety profile of RG-101, (iv) Regulus would likely need to produce extensive data to the U.S. Food and Drug Administration (“FDA”) to continue clinical trials of RG-101, and (v) as a result of the foregoing, Defendants’ statements about Regulus’ business and prospects were false and misleading and/or lacked a reasonable basis.
Take Action: if you suffered a loss in Regulus you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
